Shu-Ling Hoshi

Cost-effectiveness of chronic kidney disease mass screening test in Japan

Masahide Kondo, Kunihiro Yamagata, Shu-Ling Hoshi et al. · Clinical and Experimental Nephrology · 2011 · 78 citations · Full text

Medicine, Pharmacoeconomics, Preventive Medicine +15

Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

Masahide Kondo, Shu-Ling Hoshi, Takeharu Yamanaka et al. · Breast Cancer Research and Treatment · 2010 · 74 citations

Medicine, Oncology, Breast Oncology +12

Economic evaluation of the 70-gene prognosis-signature (MammaPrint®) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan

Masahide Kondo, Shu-Ling Hoshi, Hiroshi Ishiguro et al. · Breast Cancer Research and Treatment · 2012 · 26 citations

Medicine, Oncology, Breast Oncology +13

Budget impact analysis of chronic kidney disease mass screening test in Japan

Masahide Kondo, Kunihiro Yamagata, Shu-Ling Hoshi et al. · Clinical and Experimental Nephrology · 2014 · 16 citations · Full text

Medicine, Nephrology, Preventive Medicine +14

Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan

Hiroshi Ishiguro, Masahide Kondo, Shu-Ling Hoshi et al. · Clinical Therapeutics · 2010 · 15 citations

Medicine, Oncology, Pharmacoeconomics +12